clinical trial · NCT05490446
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Myelodysplastic SyndromesTebapivat
brief summary
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
started
Nov 7, 2022
primary completion
Mar 17, 2026
completion
Mar 1, 2029
last updated
Apr 24, 2026
official title
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol